Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - baloxavir marboxil -

İsrail - İngilizce - Ministry of Health

amgen europe b.v. - panitumumab - concentrate for solution for infusion - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type ras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type ras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

m2i limited - fludeoxyglucose (18f) - solution for injection - 1-13 gbq/ml

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

roche products ltd - interferon alfa-2a - solution for injection - 3miu/0.5ml %v/v

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

roche products ltd - interferon alfa-2a - solution for injection - 4.5miu/0.5 %v/v

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

roche products ltd - interferon alfa-2a - solution for injection - 6miu/ml %v/v

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

roche products ltd - interferon alfa-2a - solution for injection - 18miu/0.6m %v/v

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

roche products ltd - interferon alfa-2a - solution for injection - 18 miu/0.5 %v/v

İsrail - İngilizce - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 3 miu / 0.5 ml - solution for injection - interferon alfa-2a - condylumata acuminata. hepatitis b,c. hairy cell leukemia. cml. aids related kaposis sarcoma. renal cell carcinoma.follicular non-hodgkin's lymphoma. patients with ajcc stage ii malignant melanoma (breslow tumour thickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

m2i limited - fludeoxyglucose (18f) - solution for injection - 1-13 gbq/ml